Ticker brief
GTBP
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
8
authors 14d
2
crowd 14d
+0.45
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-12 → 2026-10-15 · now +0.42 (−1 bearish … +1 bullish)
Who spoke2
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PennyboisTrades | C | +0.40 | 4 | +0.49 |
| @investmattallen | C | -0.42 | 4 | +0.41 |
Recent signals8of 8 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @investmattallen | +0.35 | Sees roughly $17M cash as runway while emphasizing execution risk. | · | tweet ↗ |
| 2026-10-15 | @investmattallen | +0.45 | Argues GTBP's multi-target platform creates several long-term opportunities. | · | tweet ↗ |
| 2026-10-15 | @investmattallen | +0.45 | Finds GTBP's off-the-shelf therapy approach attractive but conditions it on clinical data. | · | tweet ↗ |
| 2026-10-15 | @PennyboisTrades | +0.45 | Suggests GTBP could be the next biotech stock to break out. | · | tweet ↗ |
| 2026-10-15 | @investmattallen | +0.40 | Presents a bullish long-term thesis for GTBP's scalable cancer immunotherapy platform. | · | tweet ↗ |
| 2026-10-14 | @PennyboisTrades | +0.50 | Describes GTBP's drug platform, enrolling Phase 1 trials, FDA expansion clearance and cash runway. | · | tweet ↗ |
| 2026-10-12 | @PennyboisTrades | +0.50 | Reports FDA clearance for a new myeloma indication and upcoming clinical readouts. | · | tweet ↗ |
| 2026-10-12 | @PennyboisTrades | +0.50 | Reports FDA IND clearance for GTB-5550 in multiple myeloma with dated pipeline catalysts. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.